Sun Pharmaceutical Industries Ltd

The company said Noveltreat is indicated for chronic weight management in adults, to be used alongside a reduced-calorie diet and increased physical activity. It is available in five dose strengths, 0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL, and 2.4 mg/0.75 mL. Sematrinity, on the other hand, is indicated for adults with insufficiently controlled Type 2 diabetes mellitus as an adjunct to diet and exercise. It is available in two dose strengths: 2 mg/1.5 mL and 4 mg/3 mL. The company stated that both therapies are priced significantly lower than the innovator brand, with weekly treatment costs ranging from approximately Rs 900 to Rs 2,000 for Noveltreat and Rs 750 to Rs 1,300 for Sematrinity. Sun Pharma said the products are delivered through user-friendly, pre-filled pen devices. Noveltreat features a concealed needle designed to reduce injection-related anxiety and improve safety and dosing accuracy, while Sematrinity is offered in a multi-dose pen format with a smooth dialer for flexible and precise dose administration. The pens have been developed by global pharmaceutical device suppliers and are manufactured in Europe. Sun Pharma highlighted that GLP-1 receptor agonists, including semaglutide, are widely used for the treatment of Type 2 diabetes and obesity, offering benefits such as improved glycaemic control and reduced cardiovascular and renal risks. Citing data from the National Family Health Survey-5 (NFHS-5), the company noted that nearly one in four Indians aged 15'49 is overweight or obese, with associated risks including metabolic disorders, cardiovascular diseases, and cancer. It also referred to the ICMR INDIAB study (2023), which estimated that over 101 million people in India are living with diabetes, with a significant proportion failing to achieve glycaemic targets, underscoring the need for effective treatment options and comprehensive disease management. Kirti Ganorkar, managing director, Sun Pharmaceutical Industries, said, 'With the launch of Noveltreat and Sematrinity, our endeavour is to provide a high-quality, affordable therapy to a wider patient community in India. We are offering a comprehensive range, backed by our decades of expertise in manufacturing complex medicines. To further support patients, we are also introducing a holistic patient support program intended to guide them throughout their treatment journey'. Sun Pharmaceutical Industries is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and active pharmaceutical ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to global market. It is the largest pharmaceutical company in India. The company has reported a 16.03% rise in consolidated net profit to Rs 3,368.81 crore on a 13.49% increase in revenue to Rs 15,520.54 crore in Q3 FY26 over Q3 FY25. The counter rose 1.90% to settle at Rs 1,777.45 on the BSE. Powered by Capital Market - Live

Sun Pharmaceutical Industries announced the launch of its semaglutide injection under the brand names Noveltreat and Sematrinity in India, in all strengths. Noveltreat is indicated for chronic weight management in adults as an adjunct to a reduced calorie diet & increased physical activity and is available in five dose strengths ' 0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL, and 2.4 mg/0.75 mL. Sematrinity is indicated for treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet & exercise and is available in two dose strengths ' 2 mg/1.5 mL and 4 mg/3 mL. Priced significantly lower than the innovator brand, weekly therapy costs, from initiation to the highest dose, range from approximately Rs 900 to Rs 2,000 for Noveltreat and Rs 750 to Rs 1,300 for Sematrinity, supporting greater affordability.Powered by Capital Market - Live

The FDA regulatory action date for this sBLA is expected by 29 October 2026. ILUMYA (tildrakizumab-asmn) is a humanized lgG1/k monoclonal antibody designed to selectively bind to the p19 subunit of interleukin-23 (IL-23) and inhibit its interaction with the IL-23 receptor, leading to inhibition of the release of pro-inflammatory cytokines and chemokines. ILUMYA is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, in the United States. ILUMYA has also been approved for moderate-to-severe plaque psoriasis in India, Australia, Canada, China and Japan, and under the brand name ILUMETRI in Europe, where it is marketed by Almirall. The company said that if approved, the application would add a new indication for ILUMYA. The therapy was approved by the FDA in 2018 for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Supplemental approvals for scalp and nail plaque psoriasis were granted in April 2024 and December 2025, respectively. ILUMYA has also received marketing authorization from over 55 worldwide health authorities since its original approval, including in India, Japan, the European Union, China, Australia and Canada. Since its approval, ILUMYA has supported nearly 140,000 patients worldwide with durable skin clearance and a well-characterized safety profile through 5 years of clinical follow-up. Additionally, real-world experience has shown strong adherence and persistence, helping patients stay on treatment long-term. ILUMYA has been endorsed widely by dermatologists in the US and globally as a trusted and effective treatment for adults with moderate-to-severe plaque psoriasis. The sBLA is based on the results from the INSPIRE-1 and INSPIRE-2 Phase 3 clinical studies evaluating the efficacy and safety of ILUMYA in adult patients with active psoriatic arthritis. Rick Ascroft, CEO, Sun Pharma North America, said, 'For many people living with psoriatic disease, joint symptoms often add another layer of burden. 'As we continue to strengthen Sun Pharma's innovative portfolio, we look forward to working with the FDA throughout the review process. As the only HHCP-administeredIL-23 biologic, our ambition is that ILUMYA becomes a differentiated first-choice advanced systemic treatment for active psoriatic arthritis.' Sun Pharmaceutical Industries is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and active pharmaceutical ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to global market. It is the largest pharmaceutical company in India. The company has reported a 16.03% rise in consolidated net profit to Rs 3,368.81 crore on a 13.49% increase in revenue to Rs 15,520.54 crore in Q3 FY26 over Q3 FY25. The counter rose 0.37% to Rs 1,789.15 on the BSE. Powered by Capital Market - Live

Sun Pharmaceutical Industries Ltd rose for a fifth straight session today. The stock is quoting at Rs 1834.9, up 1.22% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 1.03% on the day, quoting at 24010.95. The Sensex is at 77280.41, down 1.18%. Sun Pharmaceutical Industries Ltd has added around 7% in last one month. Meanwhile, Nifty Pharma index of which Sun Pharmaceutical Industries Ltd is a constituent, has added around 4.99% in last one month and is currently quoting at 23253.65, up 1.08% on the day. The volume in the stock stood at 11.22 lakh shares today, compared to the daily average of 23.65 lakh shares in last one month. The benchmark March futures contract for the stock is quoting at Rs 1831.8, up 0.59% on the day. Sun Pharmaceutical Industries Ltd is up 9.43% in last one year as compared to a 6.86% gain in NIFTY and a 15.08% gain in the Nifty Pharma index.The PE of the stock is 99.67 based on TTM earnings ending December 25.Powered by Capital Market - Live

Sun Pharmaceutical Industries Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 1711.4, up 0.55% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.04% on the day, quoting at 25738.7. The Sensex is at 83674.2, down 0.08%. Sun Pharmaceutical Industries Ltd has dropped around 1.01% in last one month. Meanwhile, Nifty Pharma index of which Sun Pharmaceutical Industries Ltd is a constituent, has dropped around 2.45% in last one month and is currently quoting at 22200.25, down 0.07% on the day. The volume in the stock stood at 22.73 lakh shares today, compared to the daily average of 31.42 lakh shares in last one month. The benchmark February futures contract for the stock is quoting at Rs 1702.6, up 0.45% on the day. Sun Pharmaceutical Industries Ltd is down 2.36% in last one year as compared to a 8.62% spurt in NIFTY and a 1.45% spurt in the Nifty Pharma index.The PE of the stock is 93.61 based on TTM earnings ending December 25.Powered by Capital Market - Live

Profit before tax were at Rs 4,227.16 crore in Q3 FY26, up 21.59% as against Rs 3,476.4 crore in Q3 FY25. Formulation sales in India were Rs 49,98.59 crore, registering a growth of 16.2%. India Formulation sales accounted for 32.3% of total consolidated sales. Formulation sales in the US were $477 million, marginally up by 0.6%. Innovative Medicines continued to grow offsetting the decline in generics business. US sales accounted for approximately 27.5% of total consolidated sales. Emerging Markets formulations sales were $337 million, up by 21.6% and accounted for 19.4% of total consolidated sales. Formulation sales in Rest of World (RoW) markets were $296 million, up by 14.5% and accounted for 17.1% of total consolidated sales. Global Innovative Medicines sales were $423 million for Q3 FY26. This included a milestone income of $55 million. Ex-milestone, Global Innovative Medicines sales were up 13.2% and accounted for 21.2% of sales. For Q3 FY26, external sales of API were Rs 541.2 crore, down by 4.7%. Sun Pharma's R&D efforts span both innovative and generic businesses, and the company continues to invest in building a robust pipeline for various markets. Sun's innovative R&D pipeline includes five novel entities in the clinical stage. The company has a comprehensive product offering in the US market, consisting of 550 approved ANDAs, while 116 ANDA filings await US FDA approval, including 28 tentative approvals. During the quarter, two ANDAs were filed, and two ANDAs received approval. Sun's portfolio includes 57 approved NDAs, while 14 NDAs are currently pending approval from the US FDA. The company declared an interim dividend of Rs 11 per equity share of Re 1 each for the financial year 2025'26. As intimated on 20 January 2026, the record date for determining entitlement to the interim dividend is 05 February 2026. The interim dividend shall be paid on or before 16 February 2026. Sun Pharmaceutical Industries is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to global market. It is the largest pharmaceutical company in India.Powered by Capital Market - Live

The benchmark equity indices began Sunday's session on a mixed footing in early trade, with the Sensex edging higher and the Nifty slipping marginally, as markets turned cautious ahead of the Union Budget 2026. The Nifty hovered around the 25,300 mark in early trade. Investors are gearing up for the release of the Union Budget 2026-27 today. Apart from sectoral announcements, all eyes would be on the growth projections and the fiscal deficit numbers that would be laid out by the Central Government today. Meanwhile, traders are also closely monitoring movements in the rupee, the flow of Q3 corporate earnings, and shifting geopolitical developments, all of which could influence near-term market sentiment. Metal, PSU bank and IT shares leading the fall while auto, private bank and pharma stocks advanced. At 09:25 IST, the barometer index, the S&P BSE Sensex advanced 28.66 points or 0.03% to 82,298.44. The Nifty 50 index fell 18.25 points or 0.07% to 25,306. In the broader market, the BSE 150 Mid-Cap index fell 0.77% and the BSE 250 Small-Cap index declined 0.72%. The market breadth was positive. On the BSE, 1,566 shares rose and 1,442 shares fell. A total of 164 shares were unchanged. Foreign portfolio investors (FPIs) had bought shares worth Rs 2,251.37 crore, while domestic institutional investors (DIIs) were net sellers to the tune of Rs 601.03 crore in the Indian equity market on 29 January 2026, provisional data showed. Numbers to Track: The yield on India's 10-year benchmark federal paper remain unchanged at 6.695 In the foreign exchange market, the rupee edged higher against the dollar. The partially convertible rupee was hovering at 91.9350 compared with its close of 91.9950 during the previous trading session. MCX Gold futures for 5 February 2026 settlement tumbled 9% to Rs 1,36,185. The US Dollar Index (DXY), which tracks the greenback's value against a basket of currencies, was up 0.74% to 96.99. The United States 10-year bond yield advanced 0.33% to 4.241. In the commodities market, Brent crude for March 2026 settlement advanced 23 cents or 0.33% to $69.82 a barrel. Stocks in Spotlight: Sun Pharmaceutical Industries rallied 3.13% after the company has reported a 16.03% rise in consolidated net profit to Rs 3,368.81 crore on a 13.49% increase in revenue to Rs 15,520.54 crore in Q3 FY26 over Q3 FY25. Bajaj Auto added 1.65% after the company's standalone net profit increased 18.68% to Rs 2,502.81 crore on an 18.84% jump in revenue from operations to Rs 15,220.33 crore in Q3 FY26 over Q3 FY25. AstraZeneca Pharma India shed 0.08%. The company said it has received approval from the CDSCO to import, sell, and distribute Durvalumab (Imfinzi) solution for infusion in 120 mg/2.4 mL and 500 mg/10 mL strengths. Global Markets: On Friday, stocks witnessed some profit taking, with technology shares remaining in a funk, even as investors largely approved of President Donald Trump's pick of Kevin Warsh to lead the Federal Reserve. The S&P 500 fell 0.43% to finish at 6,939.03, its third straight down day. The Dow Jones Industrial Average pulled back 179 points, or 0.36%, to settle at 48,892.47. The tech-heavy Nasdaq Composite underperformed, dropping 0.94%, to end the day at 23,461.82. All three indexes fell more than 1% at session lows. Spot gold and silver dropped around 9% and 28%, respectively. Over the past year, gold and silver futures have soared about 67% and 142%, respectively. Warsh's selection was likely to ease concern about Fed independence because of his experience as a Fed governor and strong stance at times against inflation. While he is likely to push for lower rates in short term as Trump wants, the financial markets view him as someone who wouldn't always follow the president's direction and maintain credibility for monetary policy.Powered by Capital Market - Live

Sun Pharmaceuticals Industries announced that the Board of Directors of the Company at its meeting held on 31 January 2026, inter alia, have recommended the interim dividend of Rs 11 per equity Share (i.e. 1100%) , subject to the approval of the shareholders.Powered by Capital Market - Live

Profit before tax were at Rs 4,227.16 crore in Q3 FY26, up 21.59% as against Rs 3,476.4 crore in Q3 FY25. Formulation sales in India were Rs 49,98.59 crore, registering a growth of 16.2%. India Formulation sales accounted for 32.3% of total consolidated sales. Formulation sales in the US were $477 million, marginally up by 0.6%. Innovative Medicines continued to grow offsetting the decline in generics business. US sales accounted for approximately 27.5% of total consolidated sales. Emerging Markets formulations sales were $337 million, up by 21.6% and accounted for 19.4% of total consolidated sales. Formulation sales in Rest of World (RoW) markets were $296 million, up by 14.5% and accounted for 17.1% of total consolidated sales. Global Innovative Medicines sales were $423 million for Q3 FY26. This included a milestone income of $55 million. Ex-milestone, Global Innovative Medicines sales were up 13.2% and accounted for 21.2% of sales. For Q3 FY26, external sales of API were Rs 541.2 crore, down by 4.7%. Sun Pharma's R&D efforts span both innovative and generic businesses, and the company continues to invest in building a robust pipeline for various markets. Sun's innovative R&D pipeline includes five novel entities in the clinical stage. The company has a comprehensive product offering in the US market, consisting of 550 approved ANDAs, while 116 ANDA filings await US FDA approval, including 28 tentative approvals. During the quarter, two ANDAs were filed, and two ANDAs received approval. Sun's portfolio includes 57 approved NDAs, while 14 NDAs are currently pending approval from the US FDA. The company declared an interim dividend of Rs 11 per equity share of Re 1 each for the financial year 2025'26. As intimated on 20 January 2026, the record date for determining entitlement to the interim dividend is 05 February 2026. The interim dividend shall be paid on or before 16 February 2026. Sun Pharmaceutical Industries is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to global market. It is the largest pharmaceutical company in India. Shares of Sun Pharmaceutical rose 0.36% to Rs 1,595 on Friday, 30 January 2026. Powered by Capital Market - Live

Net profit of Sun Pharmaceutical Industries rose 16.03% to Rs 3368.81 crore in the quarter ended December 2025 as against Rs 2903.38 crore during the previous quarter ended December 2024. Sales rose 15.12% to Rs 15469.07 crore in the quarter ended December 2025 as against Rs 13436.94 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales15469.0713436.94 15 OPM %31.9929.84 - PBDT5448.974423.13 23 PBT4716.643792.57 24 NP3368.812903.38 16 Powered by Capital Market - Live